证券代码：000766 证券简称：通化金马 公告编号：2023-38 通化金马药业集团股份有限公司 关于部分限售股份解除限售的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示 1、通化金马药业集团股份有限公司本次解除限售股份数量为 70,000,000 股，占公司目前股份总数 966,494,707 股的 7.2427%。 2、本次申请解除股份限售的股东 4 名。 3、本次有限售条件流通股上市流通日为 2023 年 8 月 18 日。 一、本次解除限售的股份取得的基本情况及后续股本变动情况 通化金马药业集团股份有限公司（以下简称"公司"、"通化金马""上市公 司"）股东北京晋商联盟投资管理有限公司（以下简称"北京晋商"）因与财通证 券资产管理有限公司金融借款合同纠纷，其所持有公司 70,000,000 股有限售条 件的股份被浙江省杭州市中级人民法院公开拍卖，上述股份已于 2023 年 7 月 11 日通过淘宝网司法拍卖网络平台竞价全部成交。其中陈新凯以最高应价胜出竞得 北京晋商被拍卖的公司 10,000,000 股股份；余奉昌以最高应价胜出 ...

Group 1: Company Overview and Activities - The company is Tonghua Jinma Pharmaceutical Group Co., Ltd., with stock code 000766 [1] - The investor relations activity was held on May 22, 2023, via an online platform [1] - Participants included the company's board members and investors [1] Group 2: New Drug Development - The new drug, Amber Hydrogen Amino Acids Tablets, is in Phase III clinical trials, currently undergoing inspection and correction [1][2][3] - The company is closely monitoring the drug's development and will disclose information as required by regulations [1][2][3] - Reports suggest that 13 products, including the new drug, are expected to be launched before 2024 [1] Group 3: Financial and Operational Concerns - The company is addressing short-term and long-term debt management to reduce annual interest expenses [2] - Marketing expenses are currently aligned with sales scale, but the company plans to enhance management to control these costs [2] - The liquidity issues in the secondary market are acknowledged, and the company aims to maintain steady operational performance [2] Group 4: Regulatory and Disclosure Practices - The company emphasizes compliance with information disclosure obligations regarding new drug approvals and developments [1][2][3] - There is a focus on maintaining confidentiality around new drug progress, leading to standardized responses to inquiries [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，通化金马药业集团股份有限公司（以下 简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限 公司共同举办的"2023 年吉林辖区上市公司网上集体业绩说明会"，现将有关事 项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景网"投资者关系互动平台"（http://ir.p5w.net）参 与公司业绩说明会,时间为 2023 年 5 月 22 日（星期一）14:00 至 16:00。 届时公司董事兼总经理战红君先生、独立董事吕桂霞女士、董事会秘书贾伟 林先生、财务总监于军先生及工作人员将通过网络在线问答互动的形式，与投资 者就 2022 年经营业绩等投资者关注的问题进行交流。期间，公司高管将全程在 线，实时回答投资者的提问。投资者可于 2023 年 5 月 19 日（星期五）17：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面， 欢迎广大投资者积极参与。 证券代码：0 ...

Financial Performance - The company's revenue for Q1 2023 was ¥308,557,426.09, a decrease of 13.70% compared to ¥357,550,409.09 in the same period last year[28]. - Total operating revenue for the current period is $308.56 million, down 13.68% from $357.55 million in the previous period[37]. - Operating profit for the current period is $5.73 million, down 13.76% from $6.65 million in the previous period[38]. - Net profit attributable to shareholders was ¥6,962,447.85, representing a 20.29% increase from ¥5,788,129.66 year-on-year[28]. - Net profit increased to $6.72 million, up 20.38% from $5.58 million in the previous period[38]. - Basic earnings per share increased by 20.00% to ¥0.0072 from ¥0.0060 in the same period last year[28]. - Basic and diluted earnings per share for the current period are both $0.0072, compared to $0.0060 in the previous period[39]. Assets and Liabilities - Total assets decreased from CNY 4,685,114,987.39 to CNY 4,500,521,306.00, a decline of about 3.9%[9]. - Total assets at the end of the reporting period were ¥4,500,521,306.00, a decrease of 3.94% from ¥4,685,114,987.39 at the end of the previous year[28]. - Total liabilities decreased from CNY 2,316,613,744.76 to CNY 2,125,298,762.67, a reduction of approximately 8.2%[9]. - The company’s long-term borrowings remained stable at CNY 1,563,550,000.00[9]. Cash Flow and Equivalents - Cash and cash equivalents decreased from CNY 336,821,630.18 at the beginning of the year to CNY 219,533,073.55 by March 31, 2023, representing a decline of approximately 34.8%[7]. - Cash and cash equivalents decreased by 34.82% to ¥219,533,073.55 due to loan repayments during the reporting period[30]. - The net increase in cash and cash equivalents was -$18,441,114.70, compared to a decrease of -$44,011,207.79 in the prior period[55]. - The ending balance of cash and cash equivalents stood at $216,764,113.25, down from $235,205,227.95 at the beginning of the period[55]. Income and Expenses - The company reported a total non-operating income of CNY 2,213,254.24 during the reporting period[2]. - The company reported a government subsidy income of CNY 2,386,717.51 during the reporting period[2]. - Other income rose by 38.15% to ¥2,386,717.51, mainly due to increased government subsidies[30]. - Total operating costs decreased to $300.49 million, a reduction of 12.73% from $344.32 million in the previous period[37]. - Research and development expenses increased to $9.33 million, up 11.15% from $8.39 million in the previous period[37]. - Sales expenses decreased to $162.41 million, down 18.63% from $199.60 million in the previous period[37]. Financing Activities - The company applied for a loan of up to CNY 90 million from Guangfa Bank to support its operational needs[6]. - Short-term borrowings increased significantly by 419.59% to ¥130,117,500.00, attributed to new bank loans[30]. - The net cash flow from financing activities was negative at -$118.78 million, a significant decrease of 170.80% compared to -$43.86 million in the previous period[46]. - Cash inflow from financing activities totaled $130,000,000.00, with cash outflow for debt repayment reaching $227,200,000.00, resulting in a net cash flow from financing activities of -$118,784,542.88[55]. Equity - The company’s total equity increased from CNY 2,368,501,242.63 to CNY 2,375,222,543.33, an increase of about 0.3%[9]. - The company's total equity attributable to shareholders was ¥2,343,821,861.62, a marginal increase of 0.30% from ¥2,336,859,413.77 at the end of the previous year[28]. - The weighted average return on net assets was 0.30%, slightly up from 0.25% in the previous year[28].

Corporate Governance - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management [10]. - The company has maintained independent ownership of its assets, ensuring no significant ownership disputes exist [12]. - The company has a robust corporate governance structure, with clear separation of powers among the board, supervisory board, and management [13]. - The company has improved its corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among shareholders, the board of directors, and management [30]. - The board of directors attended 7 meetings, with all members present at least once, indicating strong engagement in governance [41]. - The company has maintained a high level of attendance at shareholder meetings, with all directors participating in at least 3 meetings [41]. - The company has not reported any instances of directors failing to attend meetings consecutively, reflecting stable governance practices [41]. - The company has established a complete governance structure to ensure the protection of shareholder and creditor rights [100]. - The company has committed to maintaining an independent organizational structure and management system [113]. - The company has established independent financial accounting systems and management practices to ensure operational integrity [141]. Shareholder Relations - The company has actively monitored shareholder interests and ensuring equal rights for all shareholders [9]. - The company is committed to timely and efficient decision-making processes to protect the rights of all shareholders [28]. - The company has engaged in multiple investor communications throughout 2022, discussing operational conditions and new drug developments [27]. - The company has not provided any materials to investors during its communications, focusing solely on operational updates [27]. - The company has confirmed that all commitments made during the acquisition process have been fulfilled [116]. - The company has committed to reducing and standardizing related party transactions, ensuring fair pricing based on market standards [107]. - The company has guaranteed the independence of its financial decisions and operations, ensuring no interference from controlling shareholders [113]. - The company has confirmed that there are no competing businesses controlled by the major shareholder, ensuring no conflicts with the company's operations [138]. Financial Performance - The company reported a positive net profit for the reporting period, with the parent company's distributable profits being positive but no cash dividend distribution plan proposed [48]. - The company reported a total registered capital of 100 million yuan for its subsidiary, Harbin Saint Tai Biological Pharmaceutical Co., Ltd., with total assets of approximately 2.6 billion yuan [72]. - The subsidiary generated operating income of approximately 705 million yuan and a net profit of about 752 million yuan during the reporting period [72]. - The company has not reported any non-operational fund occupation by major shareholders or related parties during the reporting period [158]. - The company has not undergone any bankruptcy restructuring during the reporting period, reflecting financial stability [149]. Environmental Compliance - The average COD discharge concentration was 12.73 mg/L, and ammonia nitrogen discharge concentration was 0.148 mg/L, complying with relevant pollution discharge standards [60]. - The company has a total COD discharge of 3.28 tons and ammonia nitrogen discharge of 0.038 tons, with no exceedance of discharge limits reported [60]. - The company has a total of 1 wastewater discharge outlet located at the sewage station, ensuring compliance with environmental regulations [60]. - The company has a pollution discharge permit valid until November 20, 2027, ensuring adherence to environmental protection laws [59]. - The company has implemented advanced pollution control technologies, achieving a desulfurization efficiency of 90% and a dust removal efficiency of 99.5% [96]. - The company has invested CNY 1,929,041.50 in environmental governance and protection during the reporting period [99]. - The company has implemented emergency response plans for sudden environmental events [122]. - The company emphasizes internal management and compliance to strengthen its governance structure and risk control [78]. Research and Development - The company is committed to enhancing its research and development capabilities to ensure the successful completion of product development and market launch goals [57]. - The company plans to accelerate key R&D projects, including the development of new drugs, to enhance product technology and market competitiveness [78]. - The company has identified risks associated with new product development, emphasizing the need for careful project selection and effective risk management mechanisms [57]. Employee Management - The total number of employees at the end of the reporting period was 1,696, with 709 in the parent company and 987 in major subsidiaries [63]. - The employee composition included 880 production personnel, 314 sales personnel, 228 technical personnel, 64 financial personnel, and 210 administrative personnel [63]. - The educational background of employees showed that 307 held a bachelor's degree or higher, 430 had a college diploma, 489 had high school or vocational education, and 470 had education below high school [63]. - The company has implemented targeted employee training programs to enhance skills and improve overall team collaboration [65]. - The company has implemented a training plan to enhance employee skills and capabilities, aligning with its strategic goals [47]. Risk Management - The company faces risks related to environmental protection and safety production, which may impact operational goals [80]. - The company has not experienced any penalties or corrective actions during the reporting period, indicating stable operational compliance [150]. - The company has not reported any significant changes in project feasibility during the reporting period [89]. - The company has not reported any major contracts or high-risk entrusted financial management situations during the reporting period [177][175]. Investment and Capital Management - The company has invested a total of 1,687,461,483.26 yuan in fundraising projects as of December 31, 2022 [88]. - The company has not changed any fundraising projects during the reporting period [93]. - The company has not sold any significant assets during the reporting period [94]. - The company reported a total guarantee amount of 220,200,000 RMB during the reporting period, with an actual guarantee amount of 158,200,000 RMB for Harbin Shengtai Biological Pharmaceutical Co., Ltd. [173]. - The total approved guarantee amount at the end of the reporting period is 190,200 [188]. - Actual guarantee balance at the end of the reporting period is 163,000, representing 69.75% of the company's net assets [188]. - The total amount of guarantees exceeding 50% of net assets is 163,000 [188]. Social Responsibility - The company actively participated in social welfare and charity, promoting employment for over 200 individuals through partnerships with educational institutions [101]. - The company has adhered to the principle of "customer first," providing high-quality products and services while strengthening communication and cooperation with suppliers [125].

证券代码：000766 证券简称：通化金马 通化金马药业集团股份有限公司投资者关系活动记录表 编号：20180625 | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Group 1: Investor Relations Activities - The company participated in the 2021 Jilin Province online collective performance briefing on May 14, 2021 [1] - The event was held on the "Investor Relations Interactive Platform" provided by Shenzhen Panorama Network Co., Ltd. [1] Group 2: Key Questions and Answers - Question about whether the company's drugs will be included in the medical insurance directory this year; the company is monitoring the situation [1][2] - Inquiry regarding the company's plans for share repurchase; currently, there are no plans for share buyback [1][2] - Question about other new drugs in development besides the Amber Dihydroaminoacridine Tablets; the company has two invested drug research institutions [2] - Inquiry about the resolution of the company's debt issues related to the controlling shareholder's equity pledge dispute, which is currently in judicial proceedings [2] - Question regarding the timeline for the new drug launch; the Amber Dihydroaminoacridine Tablets have completed enrollment of 600 cases, with results expected by July or August 2021 [2]

Financial Performance - The company's revenue for Q3 2022 was ¥320,028,100.12, representing a 7.15% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥4,934,969.58, a significant increase of 168.78% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,816,207.15, up 126.94% from the previous year[3]. - Basic earnings per share for Q3 2022 were ¥0.0051, an increase of 168.92% year-on-year[3]. - Total operating revenue for the current period is CNY 1,013,753,250.35, a decrease of 6.44% compared to CNY 1,083,496,299.71 in the previous period[12]. - Net profit for the current period is CNY 11,726,341.24, down from CNY 14,755,027.29, representing a decline of 20.56%[13]. - Earnings per share (EPS) for the current period is CNY 0.0129, compared to CNY 0.0163 in the previous period, a decrease of 20.87%[14]. - The total comprehensive income attributable to shareholders of the parent company is CNY 12,464,829.48, down from CNY 15,783,388.55, a decrease of 20.66%[14]. Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥88,676,122.92, reflecting a 90.71% increase compared to the same period last year[3]. - The net cash flow from operating activities for the current period is ¥88,676,122.92, an increase of 90.5% compared to ¥46,498,512.34 in the previous period[16]. - Total cash inflow from operating activities is ¥1,074,408,967.19, down 7.2% from ¥1,157,570,001.91 in the previous period[15]. - Cash outflow from operating activities totals ¥985,732,844.27, a decrease of 11.3% compared to ¥1,111,071,489.57 in the previous period[16]. - The company reported a net cash flow from investing activities of -¥15,353,252.35, a decline from a positive cash flow of ¥10,437,192.56 in the previous period[16]. - Cash inflow from financing activities is ¥1,607,000,000.00, significantly higher than ¥27,399,900.00 in the previous period[16]. - Cash outflow from financing activities increased to ¥1,708,327,368.30 from ¥255,023,019.56 in the previous period[16]. - The ending balance of cash and cash equivalents is ¥174,697,669.66, down from ¥243,837,836.25 in the previous period[16]. - The company received ¥2,160.12 in tax refunds, compared to none in the previous period[15]. - The total cash outflow for investing activities is ¥20,478,485.27, slightly up from ¥20,284,082.29 in the previous period[16]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥4,572,028,207.89, a decrease of 1.48% from the end of the previous year[3]. - The company's total current assets as of September 30, 2022, amount to ¥1,117,099,235.59, a decrease from ¥1,151,684,009.21 at the beginning of the year[10]. - The total assets of the company are ¥4,572,028,207.89, down from ¥4,640,791,421.63[10]. - The total non-current assets are ¥3,454,928,972.30, down from ¥3,489,107,412.42[10]. - The total current liabilities amount to ¥562,108,879.70, significantly reduced from ¥2,027,548,716.60[10]. - Total liabilities amount to CNY 2,220,989,414.39, a decrease from CNY 2,301,478,969.37, reflecting a reduction of 3.52%[11]. - Long-term borrowings increased to ¥1,575,820,000.00 from ¥183,750,000.00[10]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,608[7]. - The largest shareholder, Yu Lanjun, holds 19.66% of shares, totaling 190,000,000 shares, with 150,000,000 shares pledged[7]. - The company's equity attributable to shareholders increased to ¥2,319,172,894.35, a rise of 0.54% compared to the end of the previous year[3]. - Total equity attributable to shareholders of the parent company is CNY 2,319,172,894.35, an increase from CNY 2,306,708,064.87, showing a growth of 0.54%[11]. Research and Development - Research and development expenses for the year-to-date period were ¥24,238,112.30, an increase of 45.64% compared to the same period last year[5]. - Research and development expenses increased to CNY 24,238,112.30 from CNY 16,642,133.39, marking a rise of 45.66%[12]. Other Financial Information - The company received government subsidies amounting to ¥2,457,710.56 in Q3 2022, contributing to its non-recurring gains[4]. - The company reported a significant decrease in investment income, with a loss of ¥3,746,157.64, down 138.32% year-on-year[5]. - Financial expenses for the current period are CNY 57,056,147.81, slightly down from CNY 59,576,109.93, a decrease of 4.23%[12]. - Deferred income decreased to CNY 73,669,209.18 from CNY 78,897,735.40, a decline of 6.67%[11]. - The company has not undergone an audit for the third quarter report[17].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥693,725,150.23, a decrease of 11.61% compared to ¥784,818,175.45 in the same period last year[11]. - The net profit attributable to shareholders was ¥7,529,859.90, down 67.20% from ¥22,958,542.68 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥3,722,972.58, a decline of 76.71% compared to ¥15,984,176.81 in the previous year[11]. - The basic earnings per share were ¥0.0078, down 67.23% from ¥0.0238 in the same period last year[11]. - The diluted earnings per share were also ¥0.0078, reflecting the same percentage decrease as the basic earnings per share[11]. - Operating profit was ¥18,530,551.00, down 58.10% year-on-year[22]. - Total profit amounted to ¥18,481,743.32, reflecting a decline of 56.82% compared to the previous year[22]. - The company reported a net loss of CNY 2,403,334,263.22 as of June 30, 2022, compared to a loss of CNY 2,410,864,123.12 at the beginning of the year[104]. - The company reported a net loss of ¥13,880,560.33 for the first half of 2022, compared to a net profit of ¥10,429,684.43 in the same period of 2021[111]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 496.25%, reaching ¥58,097,322.65, compared to ¥9,743,732.72 in the same period last year[11]. - The company reported a net cash outflow from investing activities of ¥9,430,665.56, a 160.69% decline year-on-year[30]. - The company reported a net cash outflow from investment activities of ¥6,292,860.94, a decrease from a net inflow of ¥6,874,058.29 in the previous year[115]. - Cash flow from financing activities resulted in a net outflow of ¥68,223,115.43, compared to a net outflow of ¥61,351,304.78 in the same period last year[115]. - The ending balance of cash and cash equivalents was ¥66,849,336.81, down from ¥183,523,839.97 at the end of the previous year[115]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,616,142,737.74, a slight decrease of 0.53% from ¥4,640,791,421.63 at the end of the previous year[11]. - The total liabilities as of June 30, 2022, were CNY 2,269,754,047.57, slightly down from CNY 2,301,478,969.37 at the beginning of the year[104]. - Cash and cash equivalents decreased to ¥278,913,905.28, representing 6.04% of total assets[35]. - Accounts receivable increased to ¥413,642,073.48, making up 8.96% of total assets[35]. - The company's total equity decreased to CNY 4,154,417,954.39 from CNY 4,168,298,514.72, a decline of 0.3%[106]. Research and Development - R&D investment increased to ¥21,355,042.90, a 50.88% rise compared to the previous year[30]. - Research and development expenses increased significantly to CNY 18,946,335.68, up from CNY 7,707,267.19, marking a rise of 146.5%[107]. - The company is advancing the Phase III clinical trial of its new drug, Succinic Acid Dihydrochloride Tablets, with pharmaceutical research completed[25]. - The company has acquired a company developing a new Alzheimer's treatment, enhancing its R&D capabilities in the pharmaceutical sector[26]. Market and Industry Position - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales of various medical products[18]. - The main products include compound probiotics, rheumatism pain relief capsules, and various traditional Chinese medicine formulations[18]. - The future outlook for the traditional Chinese medicine industry is optimistic, driven by increasing healthcare awareness and government support[18]. - The company focused on enhancing sales channels and expanding market presence, particularly in underdeveloped areas[24]. Corporate Governance and Shareholder Matters - The actual controller of Tonghua Jinma Pharmaceutical Group Co., Ltd. has changed to Mr. Yu Lanjun, with the announcement made on June 10, 2022[64]. - The company reported a significant change in control, with the major shareholder now being Mr. Yu Lanjun as of June 10, 2022[67]. - The company has committed to maintaining the independence of its operations, ensuring that key management personnel do not hold positions in other companies controlled by the major shareholder[68]. - The company has established measures to ensure compliance with market standards in related party transactions[66]. - The company has confirmed that there are no existing competitive businesses under the control of Mr. Zhang Yufu[66]. Environmental and Social Responsibility - The average COD concentration of wastewater in the first half of 2022 was 10.67 mg/L, with a total of 127,831 tons of wastewater treated[59]. - The company achieved a COD emission reduction of 112 tons and an ammonia nitrogen reduction of 0.092 tons in the first half of 2022[59]. - The company invested 8.2 million yuan to build a 1,000 t/a wastewater treatment plant, which has been operational since 2018[59]. - The company actively participated in poverty alleviation and rural revitalization efforts as part of its social responsibility initiatives[63]. Compliance and Legal Matters - There were no significant litigation or arbitration matters during the reporting period[72]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[70]. - The company has no bankruptcy reorganization matters during the reporting period[70]. Accounting and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial statements accurately reflect its financial position and operating results[137]. - The company’s accounting policies and estimates are tailored to its operational characteristics, following relevant accounting standards[136]. - The company’s consolidated financial statements include all subsidiaries under its control, reflecting the overall financial status and performance of the group[145].

Financial Performance - The company's revenue for Q1 2022 was ¥357,550,409.09, a decrease of 6.64% compared to ¥382,987,117.99 in the same period last year[1] - Net profit attributable to shareholders increased by 42.19% to ¥5,788,129.66 from ¥4,070,763.78 year-on-year[1] - The net profit after deducting non-recurring gains and losses surged by 360.91% to ¥4,263,414.14 compared to ¥924,990.49 in the previous year[1] - Basic and diluted earnings per share rose by 42.86% to ¥0.0060 from ¥0.0042 year-on-year[1] - Total operating revenue for Q1 2022 was CNY 357,550,409.09, a decrease of 6.4% from CNY 382,987,117.99 in Q1 2021[13] - Net profit for Q1 2022 was CNY 5,583,342.14, an increase of 49.5% compared to CNY 3,731,956.70 in Q1 2021[14] Cash Flow - Operating cash flow for the period was ¥6,770,028.14, reflecting a significant increase of 357.11% from ¥1,481,060.68 in the same quarter last year[1] - Operating cash inflow for the current period was ¥306,207,804.95, a decrease of 15.3% from ¥361,364,592.59 in the previous period[16] - Operating cash outflow for the current period was ¥299,437,776.81, down 16.8% from ¥359,883,531.91 in the previous period[16] - Net cash flow from operating activities increased to ¥6,770,028.14, compared to ¥1,481,060.68 in the previous period[16] - Cash flow from investment activities resulted in a net outflow of ¥6,916,875.85, an improvement from a net outflow of ¥10,418,366.92 in the previous period[17] - Cash flow from financing activities showed a net outflow of ¥43,864,360.08, slightly better than the previous period's outflow of ¥44,971,072.19[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,634,838,733.13, a slight decrease of 0.13% from ¥4,640,791,421.63 at the end of the previous year[1] - The company's cash and cash equivalents decreased to approximately RMB 258.43 million from RMB 301.59 million, reflecting a decline of about 14.3%[10] - Accounts receivable increased to approximately RMB 426.97 million, up from RMB 350.61 million, indicating a growth of about 21.7%[10] - Inventory decreased to approximately RMB 367.26 million from RMB 384.58 million, a reduction of about 4.5%[11] - Total liabilities decreased slightly to CNY 2,289,942,938.73 from CNY 2,301,478,969.37 in the previous year[12] - The company’s total liabilities included short-term borrowings of RMB 40 million, remaining stable compared to the previous period[11] Research and Development - The company's R&D expenses increased by 165.57% to ¥8,393,049.09 from ¥3,160,401.87 in the same period last year, indicating a strong focus on innovation[3] - R&D expenses increased significantly to CNY 8,393,049.09, up 165.5% from CNY 3,160,401.87 in the same period last year[13] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,300, with no preferred shareholders[4] - The proportion of shares held by the largest shareholder, Yu Lanjun, increased to 19.66% after the judicial auction of shares held by Beijing Jinshang[9] - The company is facing legal disputes involving its major shareholder, which has resulted in a reduction of shareholding percentage[9] Other Financial Metrics - The weighted average return on net assets was 0.25%, up from 0.18% in the previous year[1] - The company reported a total of 1,149.82 million in current assets, slightly down from 1,151.68 million at the beginning of the year[11] - Long-term equity investments were valued at approximately RMB 55.11 million, a minor decrease from RMB 56.03 million[11] - The company reported a significant reduction in sales expenses to CNY 199,604,097.25, down 13.2% from CNY 230,032,417.37 in the previous year[13] Audit Status - The first quarter report was not audited[18]